Corcept Therapeutics (NASDAQ:CORT) is scheduled to release its earnings data after the market closes on Thursday, February 22nd. Analysts expect Corcept Therapeutics to post earnings of $0.18 per share for the quarter.
Corcept Therapeutics (NASDAQ CORT) opened at $15.98 on Tuesday. Corcept Therapeutics has a 52 week low of $8.14 and a 52 week high of $25.96. The company has a market capitalization of $1,823.70, a P/E ratio of 55.11 and a beta of 1.68.
A number of brokerages have commented on CORT. Piper Jaffray Companies set a $30.00 target price on Corcept Therapeutics and gave the company a “buy” rating in a research note on Monday, February 5th. BidaskClub downgraded Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, February 13th. Stifel Nicolaus decreased their target price on Corcept Therapeutics from $25.00 to $20.00 and set a “buy” rating for the company in a research note on Monday, February 5th. Finally, Zacks Investment Research downgraded Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 3rd. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $21.00.
In other news, insider Robert S. Fishman sold 8,000 shares of the business’s stock in a transaction that occurred on Monday, January 8th. The stock was sold at an average price of $18.67, for a total transaction of $149,360.00. Following the completion of the transaction, the insider now directly owns 8,000 shares in the company, valued at $149,360. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last quarter, insiders have sold 24,000 shares of company stock valued at $415,920. Insiders own 19.20% of the company’s stock.
About Corcept Therapeutics
Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.